Literature DB >> 24425692

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.

Christen L Andersen1, Nana B Mortensen, Tobias W Klausen, Hanne Vestergaard, Ole W Bjerrum, Hans C Hasselbalch.   

Abstract

Entities:  

Keywords:  clinical response; monotherapy; post-polycythemia vera; primary myelofibrosis; vorinostat

Mesh：

Substances：

Year:  2014        PMID： 24425692      PMCID： PMC4007932          DOI： 10.3324/haematol.2013.096669

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  The myeloproliferative disorders.

Authors:  Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

2.  Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.

Authors:  Jin Lee
Journal:  Ann Hematol       Date:  2008-11-22       Impact factor: 3.673

3.  Improving survival trends in primary myelofibrosis: an international study.

Authors:  Francisco Cervantes; Brigitte Dupriez; Francesco Passamonti; Alessandro M Vannucchi; Enrica Morra; John T Reilly; Jean-Loup Demory; Elisa Rumi; Paola Guglielmelli; Elisa Roncoroni; Ayalew Tefferi; Arturo Pereira
Journal:  J Clin Oncol       Date:  2012-07-23       Impact factor: 44.544

Review 4.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

5.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

Review 6.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

7.  A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

Authors:  John Mascarenhas; Min Lu; Timmy Li; Bruce Petersen; Tsivia Hochman; Vesna Najfeld; Judith D Goldberg; Ronald Hoffman
Journal:  Br J Haematol       Date:  2013-01-21       Impact factor: 6.998

8.  The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

Authors:  V Guerini; V Barbui; O Spinelli; A Salvi; C Dellacasa; A Carobbio; M Introna; T Barbui; J Golay; A Rambaldi
Journal:  Leukemia       Date:  2007-12-13       Impact factor: 11.528

9.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528

10.  A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.

Authors:  Christen L Andersen; Mary F McMullin; Elisabeth Ejerblad; Sonja Zweegman; Claire Harrison; Savio Fernandes; David Bareford; Steven Knapper; Jan Samuelsson; Eva Löfvenberg; Olle Linder; Bjørn Andreasson; Erik Ahlstrand; Morten K Jensen; Ole W Bjerrum; Hanne Vestergaard; Herdis Larsen; Tobias W Klausen; Torben Mourits-Andersen; Hans C Hasselbalch
Journal:  Br J Haematol       Date:  2013-06-11       Impact factor: 6.998
View more
  10 in total

Review 1.  Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

Review 3.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 4.  Pharmacotherapy of Myelofibrosis.

Authors:  Douglas Tremblay; Bridget Marcellino; John Mascarenhas
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

5.  HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Authors:  Lanzhu Yue; Vasundhara Sharma; Nathan P Horvat; Afua A Akuffo; Matthew S Beatty; Cem Murdun; Christelle Colin; Julia M R Billington; William E Goodheart; Eva Sahakian; Ling Zhang; John J Powers; Narmin E Amin; Que T Lambert-Showers; Lancia N Darville; Javier Pinilla-Ibarz; Gary W Reuther; Kenneth L Wright; Chiara Conti; Jennifer Y Lee; Xiaozhang Zheng; Pui Yee Ng; Matthew W Martin; C Gary Marshall; John M Koomen; Ross L Levine; Amit Verma; H Leighton Grimes; Eduardo M Sotomayor; Zonghong Shao; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

Review 6.  Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Authors:  G Barosi; A Tefferi; C Besses; G Birgegard; F Cervantes; G Finazzi; H Gisslinger; M Griesshammer; C Harrison; R Hehlmann; S Hermouet; J-J Kiladjian; N Kröger; R Mesa; M F Mc Mullin; A Pardanani; F Passamonti; J Samuelsson; A M Vannucchi; A Reiter; R T Silver; S Verstovsek; G Tognoni; T Barbui
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528

Review 7.  Erythropoiesis: insights into pathophysiology and treatments in 2017.

Authors:  Andrea Zivot; Jeffrey M Lipton; Anupama Narla; Lionel Blanc
Journal:  Mol Med       Date:  2018-03-23       Impact factor: 6.354

Review 8.  Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.

Authors:  Vasundhara Sharma; Kenneth L Wright; Pearlie K Epling-Burnette; Gary W Reuther
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

Review 9.  Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Authors:  Andrew L Sochacki; Melissa A Fischer; Michael R Savona
Journal:  Onco Targets Ther       Date:  2016-04-15       Impact factor: 4.147

Review 10.  Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Authors:  Holly L Geyer; Amylou C Dueck; Robyn M Scherber; Ruben A Mesa
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.